What is Mazdutide?
Mazdutide (IBI362) is a lipidated peptide based on the oxyntomodulin backbone that activates both the GLP-1 and glucagon receptors. It is supplied here as a lyophilised powder for in-vitro laboratory research only.
Key concepts
- IBI362 is the research designation for mazdutide
- Built on the oxyntomodulin backbone, which is natively dual-acting
- GLP-1 + glucagon receptor agonist, with no designed GIP activity
- Useful for separating GIP from glucagon receptor contributions
- Batch-specific certificates of analysis are the primary reference for purity and identity
- Mazdutide is investigational and unapproved for human or veterinary use in the UK and US
The oxyntomodulin backbone
Oxyntomodulin is a naturally occurring gut peptide that is itself a weak dual agonist at the GLP-1 and glucagon receptors. Analogue programmes take that natural dual activity as a starting point and engineer it for potency and duration, which is the lineage mazdutide belongs to.
That origin is why mazdutide is usually described as an oxyntomodulin analogue rather than as a GLP-1 analogue with added glucagon activity. The dual activity is native to the scaffold, not bolted on.
Receptor profile
Mazdutide engages the GLP-1 receptor and the glucagon receptor and does not carry designed GIP receptor activity. Set against tirzepatide (GIP + GLP-1) and retatrutide (GIP + GLP-1 + glucagon), it isolates a different pairing, which makes it useful for separating the contributions of GIP and glucagon receptor activity.
As with any poly-agonist, the relative potency at each receptor determines behaviour in a given model, so published potency ratios should be checked rather than assumed to be balanced.
Research context
Research interest centres on how combined incretin and glucagon receptor activity behaves relative to GLP-1 receptor activity alone, particularly in models addressing hepatic metabolism and energy expenditure where glucagon receptors are abundantly expressed.
The published record is younger and smaller than for semaglutide or tirzepatide, with much of the clinical reporting originating from programmes conducted in China. Findings should be treated as investigational.
How it is supplied for research
Biovanta Research supplies mazdutide as a single 10mg lyophilised vial, a size suited to exploratory in-vitro protocols, with an independent certificate of analysis published for the batch.
Material is supplied strictly for in-vitro laboratory research by qualified persons. It is not a medicine and is not for human or veterinary use.
Analytical verification
As with the other lipidated peptides in this library, identity and purity should be established for each batch by reversed-phase HPLC and mass spectrometry rather than assumed from the peptide’s general literature description. The certificate of analysis published for the specific mazdutide batch is the correct reference document for its purity percentage and confirmed mass, and any receptor pharmacology result should be checked against that certificate before being generalised.
Because mazdutide is a comparatively newer research compound with a smaller published analytical record than semaglutide or tirzepatide, laboratories may find fewer independent literature reference chromatograms to compare against, which makes the batch-specific certificate of analysis proportionally more important as the primary source of analytical truth.
Suitable model systems and study design
Single-receptor recombinant cell lines expressing either the GLP-1 or the glucagon receptor, each with a cAMP-based readout, are the standard approach for characterising mazdutide’s activity at each target independently, using native GLP-1 and native glucagon or established analogues as reference agonists. Because mazdutide’s designed profile excludes GIP receptor activity, including a GIP receptor assay as a negative control is a useful way to confirm receptor selectivity experimentally rather than assuming it from the design rationale alone.
Hepatocyte and adipocyte models, and rodent studies of energy expenditure and hepatic glucose output, extend this to integrated physiology; as with any poly-agonist, results from these systems should be interpreted alongside the specific potency ratio reported for the batch used, since that ratio determines which receptor’s contribution dominates a given response.
Development and regulatory status
Mazdutide is an investigational compound. It does not hold a marketing authorisation from the MHRA in the United Kingdom or the FDA in the United States, and clinical data reported to date, much of it from trials conducted in China, do not establish either efficacy or safety conclusions that would apply outside those specific trial populations and designs. Material supplied for research is intended strictly for in-vitro laboratory work and carries no dosing or human-use guidance.
Because the mazdutide clinical and regulatory record is still developing, researchers should check ClinicalTrials.gov and the primary publications directly for the current state of the evidence rather than relying on a static summary such as this one.
Strength of the current evidence
Oxyntomodulin-analogue pharmacology is well established. The mazdutide-specific clinical record is early-stage and smaller than for the better-known incretin peptides.
References
- Indexed mazdutide publications (PubMed search listing)
- Oxyntomodulin analogue literature (PubMed search listing)
- Registered mazdutide studies (ClinicalTrials.gov search listing)
Back to the Mazdutide research hub · Mazdutide research material · Certificates of analysis
Research use only. Everything on this page describes published laboratory and preclinical research into a compound supplied strictly for in-vitro research by qualified persons. It is not medical advice, it does not describe human or veterinary use, and no dosing guidance is given.